Agilex Biolabs Pty Ltd | Holly Stefl

Agilex Biolabs is recognized by the National Association of Testing Authorities (NATA) for conduct of nonclinical safety studies to OECD GLP compliance. Agilex Biolabs toxicology studies are conducted in compliance with the Queensland Animal Care and Protection Act (2001) and the Australian Code for the Care and Use of Animals for Scientific Purposes (2013). All studies are conducted with approval of a local Animal Ethics Committee according these principles. Agilex Biolabs also has a Queensland Health Drugs license to hold and use scheduled drugs. The facility operates to PC2 compliance and any studies using GMOs are conducted with a local biosafety committee approval in accordance with Australian Office of Gene Technology Regulator (OGTR) requirements.

Agilex Biolabs specialises in a number of therapeutic areas of research such as- 

- Animal Diseases
- Bacterial Infections and Mycoses
- Cardiovascular Diseases
- Chemically-induced Disorders

- CNS
- Congenital, Hereditary and Neonatal Diseases and Abnormalities
- Digestive System Diseases
- Disorders of Environmental Origin
- Endocrine System Diseases
- Eye Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Hemic and Lymphatic Diseases
- Immune System Diseases

- Immuno-oncology

- Infectious Diseases
- Male Urogenital Diseases
- Mental Disorders
- Musculoskeletal Diseases
- Neoplasms
- Nervous System Diseases
- Nutritional and Metabolic Diseases
- Occupational Diseases

- Oncology
- Otorhinolaryngologic Diseases
- Parasitic Diseases
- Pathological Conditions, Signs and Symptoms
- Respiratory Tract Diseases
- Skin and Connective Tissue Diseases
- Stomatognathic Diseases
- Virus Diseases
- Wounds and Injuries

- Vaccines